@article{d1231bc75cdd4513bedf1899f6c99218,
title = "Itch: A Paradigm of Neuroimmune Crosstalk",
abstract = "Wang and Kim highlight new discoveries in neuroscience and immunology that have directly informed emerging therapeutic approaches to itch. They outline how classical immunologic pathways integrate with newly identified itch circuits to form a paradigm of sensory neuroimmunology.",
author = "Fang Wang and Kim, {Brian S.}",
note = "Funding Information: We thank all members of the Kim lab for helpful comments and discussion. This work is supported by the Doris Duke Charitable Foundation, LEO Pharma, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (R01AR070116). B.S.K. has served as a consultant for AbbVie, Cara Therapeutics, Concert Pharmaceuticals, Incyte Corporation, LEO Pharma, Menlo Therapeutics, and Pfizer. He has also participated on the advisory board for Cara Therapeutics, Celgene Corporation, Kiniksa Pharmaceuticals, Menlo Therapeutics, Regeneron Pharmaceuticals, Sanofi Genzyme, and Theravance Biopharma. He is also the founder, chief scientific officer, and stockholder of Nuogen Pharma and a stockholder of Locus Biosciences. He has a patent pending for the use of JAK inhibitors for chronic itch. F.W. declares no competing interests. Funding Information: We thank all members of the Kim lab for helpful comments and discussion. This work is supported by the Doris Duke Charitable Foundation , LEO Pharma , and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health ( R01AR070116 ). Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = may,
day = "19",
doi = "10.1016/j.immuni.2020.04.008",
language = "English",
volume = "52",
pages = "753--766",
journal = "Immunity",
issn = "1074-7613",
number = "5",
}